微小RNA在调控血管平滑肌细胞凋亡与心血管疾病的联系与临床应用

李丹, 颜渊鸳, 欧和生

中国药学杂志 ›› 2019, Vol. 54 ›› Issue (8) : 603-607.

PDF(1012 KB)
中国药学杂志
PDF(1012 KB)
中国药学杂志 ›› 2019, Vol. 54 ›› Issue (8) : 603-607. DOI: 10.11669/cpj.2019.08.002
·综 述·

微小RNA在调控血管平滑肌细胞凋亡与心血管疾病的联系与临床应用

  • 李丹1, 颜渊鸳1, 欧和生1,2*
作者信息 +

MicroRNAs Regulate Vascular Smooth Muscle Cell Apoptosis and Cardiovascular Disease

  • LIDan1, YANYuan-yuan1, OUHe-sheng1,2*
Author information +
文章历史 +

摘要

微小RNA(microRNAs,miRNAs)是由18~22核苷酸组成的非编码微小RNA,它在体内动态平衡调节和疾病发生发展等许多方面发挥重要作用,经研究已被证实参与心血管疾病的发病机制,包括动脉粥样硬化、心肌梗死、高血压和支架术后狭窄。miRNAs在血液循环中稳定存在,它可调控血管平滑肌细胞的增殖、分化、迁移、凋亡等,其中细胞凋亡对心血管疾病有特殊生理病理意义,因此可能是心血管疾病诊断治疗的新热点。笔者旨在综述miRNAs调控血管平滑肌细胞凋亡与心血管疾病的联系与临床应用,为miRNAs调节血管平滑肌细胞功能,参与心血管疾病的研究网络提供一定的理论依据。

Abstract

microRNAs are non-coding microRNAs composed of 18-22 nucleotides, which play an important role in many aspects such as homeostasis regulation and disease development. They have been confirmed to be involved in the pathogenesis of cardiovascular diseases, including atherosclerosis, myocardial infarction, hypertension, and stent stenosis. miRNAs are stable in the blood circulation, which are regulate the proliferation, differentiation, migration, and apoptosis of vascular smooth muscle cells. Apoptosis has special physiological and pathological significance for cardiovascular diseases, so it may be a new hot spot for the diagnosis and treatment of cardiovascular diseases. This article aims to review the association and clinical application of miRNAs in regulating vascular smooth muscle cell apoptosis and cardiovascular disease. It provides a theoretical basis for the research network of miRNAs regulating the function of vascular smooth muscle cells which involved in cardiovascular disease.

关键词

微小RNA / 心血管疾病 / 血管平滑肌细胞 / 凋亡

Key words

microRNAs / cardiovascular disease / vascular smooth muscle cells / apoptosis

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
李丹, 颜渊鸳, 欧和生. 微小RNA在调控血管平滑肌细胞凋亡与心血管疾病的联系与临床应用[J]. 中国药学杂志, 2019, 54(8): 603-607 https://doi.org/10.11669/cpj.2019.08.002
LIDan, YANYuan-yuan, OUHe-sheng. MicroRNAs Regulate Vascular Smooth Muscle Cell Apoptosis and Cardiovascular Disease[J]. Chinese Pharmaceutical Journal, 2019, 54(8): 603-607 https://doi.org/10.11669/cpj.2019.08.002
中图分类号： R54   

参考文献

[1] NAVICKAS R, GAL D, LAUCEVIIUS A, et al. Identifying circulating microRNAs as biomarkers of cardiovascular disease:a systematic review[J]. Cardiov Res, 2016, 111(4):322-337.
[2] MENS M M J, GHANBARI M. Cell cycle regulation of stem cells by microRNAs[J].Stem Cell Rev, 2018, 14(3):309-322.
[3] WANG R, REN Y, YANG J. Research progression of liver cancer treatment through differential expression of miRNAs controlled by traditional Chinese medicine[J]. Chin Pharm J(中国药学杂志),2018,53(3):169-173.
[4] WOJCIECHOWSKA A, BRANIEWSKA A, KOZAR-KAMINSKA K. MicroRNA in cardiovascular biology and disease[J]. Adv Clin Exp Med, 2017, 26(5):865-874.
[5] HASSAN M, WATARI H, ABUALMAATY A, et al. Apoptosis and molecular targeting therapy in cancer[J]. Biomed Res Int, 2014, 2014:1-23.
[6] ZHANG M J, ZHOU Y, CHEN L, et al. An overview of potential molecular mechanisms involved in VSMC phenotypic modulation[J]. Histochem Cell Biol, 2016,145(2):119-130.
[7] MOJ G, MOULIS M, ROTH L, et al. Vascular smooth muscle cell death, autophagy and senescence in atherosclerosis[J]. Cardiov Res, 2018,114(4):622-634.
[8] PFEFFER C M, SINGH A T K. Apoptosis:a target for anticancer therapy[J]. Int J Mol Sci, 2018, 19(2):E448.
[9] GOLDAR S, KHANIANI M S, DERAKHSHAN S M, et al. Molecular mechanisms of apoptosis and roles in cancer development and treatment[J]. Asian Pac J Cancer Prev, 2015, 16(6):2129-2144.
[10] ZAMAN S, WANG R, GANDHI V. Targeting the apoptosis pathway in hematologic malignancies[J]. Leuk Lymphoma, 2014,55(9):1980-1992.
[11] GREEN D R, LLAMBI F. Cell death signaling[J]. Cold Spring Harbor Perspectives In Biology, 2015, 7(12):a006080.
[12] ELBARBARY R A, MIYOSHI K, MYERS J R, et al. Tudor-SN-mediated endonucleolytic decay of human cell microRNAs promotes G1/S phase transition[J]. Science, 2017, 356(6340):859-862.
[13] YU X, LI Z. MicroRNAs regulate vascular smooth muscle cell functions in atherosclerosis (review)[J]. Int J Mol Med, 2014,34(4):923-933.
[14] FAVA C, MONTAGNANA M. Atherosclerosis is an inflammatory disease which lacks a common anti-inflammatory therapy:how human genetics can help to this issue. A narrative review[J]. Front Pharmacol, 2018, 9:55.
[15] BENNETT M R, SINHA S, OWENS G K. Vascular smooth muscle cells in atherosclerosis[J]. Circ Res, 2016, 118(4):692-702.
[16] YANG J, CHEN L, DING J, et al. MicroRNA-24 inhibits high glucose-induced vascular smooth muscle cell proliferation and migration by targeting HMGB1[J]. Gene, 2016,586(2):268-273.
[17] ZONG Y, WU P, NAI C, et al. Effect of microRNA-30e on the behavior of vascular smooth muscle cells via targeting ubiquitin-conjugating enzyme E2I[J]. Circul, 2017, 81(4):567-576.
[18] LI M, LIU Q, LEI J, et al. MiR-362-3p inhibits the proliferation and migration of vascular smooth muscle cells in atherosclerosis by targeting ADAMTS1[J]. Biochem Biophys Res Commun, 2017, 493(1):270-276.
[19] GHEIBI S, JEDDI S, KASHFI K, et al. Regulation of vascular tone homeostasis by NO and H2S: implications in hypertension[J]. Biochem Pharmacol, 2018, 149:42-59.
[20] TOUYZ R M, ALVES-LOPES R, RIOS F J, et al. Vascular smooth muscle contraction in hypertension[J]. Cardiovasc Res, 2018, 114(4):529-539.
[21] WU W H, HU C P, CHEN X P, et al. MicroRNA-130a mediates proliferation of vascular smooth muscle cells in hypertension[J]. Am J Hypertens, 2011,24(10):1087-1093.
[22] GU Q, ZHAO G, WANG Y, et al. Silencing miR-16 expression promotes angiotensin II stimulated vascular smooth muscle cell growth[J]. Cell Devel Biol, 2017, 6(1):181.
[23] DENG L,BLANCO F J,STEVENS H, et al. MicroRNA-143 Activation regulates smooth muscle and endothelial cell crosstalk in pulmonary arterial hypertension[J]. Circul Res,2015,117(10):870-883.
[24] TAKAWALE A, ZHANG P, AZAD A, et al. Myocardial overexpression of TIMP3 after myocardial infarction exerts beneficial effects by promoting angiogenesis and suppressing early proteolysis[J]. Am J Physiol Heart Circ Physiol, 2017,313(2):H224-H236.
[25] PURCELL B P, BARLOW S C, PERREAULT P E, et al. Delivery of a matrix metalloproteinase responsive hydrogel releasing TIMP-3 following myocardial infarction: effects on left ventricular remodeling[J]. Am J Physiol Heart Circ Physiol, 2018,315(4):H814-H825.
[26] YI J, AN Y. Circulating miR-379 as a potential novel biomarker for diagnosis of acute myocardial infarction[J]. Eur Rev Med Pharmacol Sci, 2018, 22(2):540-546.
[27] ZHAO H, HAN T, HONG X, et al. Adipose differentiation related protein knockdown inhibits vascular smooth muscle cell proliferation and migration and attenuates neointima formation[J]. Mol Med Rep, 2017, 16(3):3079-3086.
[28] LIU P, SU J, SONG X, et al. miR-92a regulates the expression levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 3 via sirtuin 1 signaling in hydrogen peroxide-induced vascular smooth muscle cells[J]. Mol Med Rep, 2018, 17(1):1041-1048.
[29] FU Y, ZHAO Y, LIU Y, et al. Adenovirus-mediated tissue factor pathway inhibitor gene transfer induces apoptosis by blocking the phosphorylation of JAK-2/STAT-3 pathway in vascular smooth muscle cells[J]. Cellular Signalling, 2012, 24(10):1909-1917.
[30] HE M, GONG Y, SHI J, et al. Plasma microRNAs as potential noninvasive biomarkers for in-stent restenosis[J]. PLoS One, 2014, 9(11):e112043.
[31] CHE H L, BAE I H, LIM K S, et al. Novel fabrication of microRNA nanoparticle-coated coronary stent for prevention of post-angioplasty restenosis[J]. Korean Circ J, 2016, 46(1):23-32.
[32] MCDONALD R A, HALLIDAY C A, MILLER A M, et al. Reducing in-stent restenosis:therapeutic manipulation of miRNA in vascular remodeling and inflammation[J]. J Am Coll Cardiol, 2015, 65(21):2314-2327.
[33] GARERI C, IACONETTI C, SORRENTINO S, et al. miR-125a-5p Modulates phenotypic switch of vascular smooth muscle cells by targeting ETS-1[J]. J Mol Biol, 2017, 429(12):1817-1828.
[34] CHEN Z, WANG M, HUANG K, et al. MicroRNA-125b affects vascular smooth muscle cell function by targeting serum response factor[J]. Cell Physiol Biochem,2018,46(4):1566-1580.
[35] M LUCRECIA A, MAHDIEH K, ELENA E, et al. MicroRNA-27a decreases the level and efficiency of the LDL receptor and contributes to the dysregulation of cholesterol homeostasis[J]. Atherosclerosis, 2015, 242(2):595-604.
[36] KERR A G, TAM L C, HALE A B, et al. Episomal nonviral gene therapy vectors slow progression of atherosclerosis in a model of familial hypercholesterolemia[J]. Mol Ther Nucleic Acids, 2016, 5(11):e383.
[37] ZAMBRANO T. MicroRNAs and response to statins in patients with hypercholesterolemia:from basic research to precision medicine[J]. Pharmacogenomics, 2018, 19(9):748-751.

基金

国家自然科学基金项目资助(81373403)
PDF(1012 KB)

Accesses

Citation

Detail
段落导航
相关文章

/

〈 〉